Member Info for Laura2022

Please feel free.to correct me

All I can see is you wrongly saying today and Friday a move back to 50p was going to happen

Having sold a chunk 3 weeks ago at 17p I'm sorely t tempted to buy them back

As comparison

RENX is £24mln cap with $2mln of revenue and burning $6mln a year

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs.

 

I assume you meant attack back to 60p. :)

HelloDave

Posted in: WG.

Posts: 296

Price: 54.00

No Opinion

RE: We’ll see after hours I expect - who has been mopping up22 Nov 2024 19:55

Expect another attack back to 50 start of next week....

Thanks

Thanks Auson

Where was that shown ?

Shorts close

Remember a huge % shares held by II

The U turners

Hello Dave "50p heading back soon"

And others

Pretty poor standards

Takeover bids would send this ORA

The closure of the $100mln asset sale ($30mln already received)

Now

Here we go

I had predicted this..while others were jeykl and hyde

56p

Wait for more green boxes u turns lol

Another for the green bin

Valueseeker

Then don't buy and focus on YOUR investments?

You've posted 20+ times on WG

Odd

This was from KingHomer ( a poster on this board)

The New CEO Pete is very driven and has an exceptional background.

The revenue is the highest it ever has been going into a new financial year with the biggest pipeline with contracted revenues up until 2027...This alone warrants a MC in the multiples of current

The new biostats (new revenue stream) can itself produce far greater revenues that the current VT tech. (see recent presentation) Again multiples on the multiples

The Dosing tool which effectively is in two trials with NHS- Beyond Blood & Dosemerx in the US has the potential to add tens of Millions in revenue with the sheer saving it would save on the Docetaxel (Taxotere) Chemo

Docetaxel is a blockbuster cancer drug with peak global sales of £3.1 Billion and rising

Hi Andy

That was from AstraZeneca RNS today

Strange all these LSE accounts which are 5-8 years old ALL.OF A SUDDEN pop up on WG

Look like if 55-56 can break